Certara, Inc. (CERT)

Market Cap	1.87B
Revenue (ttm)	394.50M
Net Income (ttm)	-2.63M
Shares Out	162.23M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	24.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,285,719
Open	11.60
Previous Close	11.70
Day's Range	11.47 - 11.98
52-Week Range	8.64 - 16.93
Beta	1.45
Analysts	Buy
Price Target	15.60 (+35.42%)
Earnings Date	Aug 5, 2025

About CERT

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists worki...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 1,546
• Stock Exchange: NASDAQ
• Ticker Symbol: CERT
• Website: https://www.certara.com

Financial Performance

In 2024, Certara's revenue was $385.15 million, an increase of 8.70% compared to the previous year's $354.34 million. Losses were -$12.05 million, -78.23% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for CERT stock is "Buy." The 12-month stock price target is $15.6, which is an increase of 35.42% from the latest price.

Price Target

$15.6

(35.42% upside)

Analyst Consensus: Buy